Democrats’ new logic on drug pricing: Developing slightly fewer medicines is OK if it means lower prices
(By Lev Facher for STAT) WASHINGTON — Democratic lawmakers in recent weeks have begun to advance an argument long seen
Read More(By Lev Facher for STAT) WASHINGTON — Democratic lawmakers in recent weeks have begun to advance an argument long seen
Read MoreMedicare Part D drug plans provide drug benefits to millions of seniors each year. But Part D plans often make
Read More(By JoNel Aleccia, Barbara Feder Ostrov, and Donna Gordon Blankinship for Kaiser Health News) When a long, black bus bearing
Read More(By Damian Garde and Adam Feuerstein for STAT) Biogen’s decision to revisit a once-failed treatment for Alzheimer’s disease came as
Read More(By Blake Farmer for NPR) While thousands of cities and counties have banded together to sue opioid makers and distributors in
Read More(By Dennis J. Selkoe for STAT) One of the many things I’ve learned during four decades of doing research on
Read MoreSince 2000, small businesses have been responsible for creating 66 percent – almost 60 million people – are employed by
Read MoreMedicare’s annual open enrollment period, when you can make changes that take effect January 1st, is under way and closes
Read More(By Gabrielle Masson for Becker’s Hospital Review) The opioid crisis cost the U.S. at least $631 billion from 2015 to
Read MoreThe 2020 Medicare Open Enrollment season has begun and insurers are putting on the hard press to attract new baby
Read More